Critical Path Initiative

About Critical Path

The Critical Path Initiative (CPI) is FDA's national strategy for transforming the way FDA-regulated products are developed, evaluated, manufactured, and used.  More

• Frequently Asked Questions

Critical Path Opportunities Reports

• Critical Path Annual Report 2008
• FDA's Sentinel Initiative
• Critical Path Opportunities Initiated During 2007
• Critical Path Opportunities for Generic Drugs
• More

Faces Behind Critical Path

• Collaboration cornerstone of CPI... Interview with Dr. Rachel Behrman
• Making Medical Products Better, Faster, and Cheaper
• Interview on Warfarin
• Janet Woodcock Commentary on Critical Path
• More

Articles and Presentations

• FDA's Proactive Role in the Development of an Artificial Pancreas for Treating Diabetes Mellitus
• Developing new drugs for the treatment of drug resistant tuberculosis:  a regulatory perspective
• Bioinformatics Modernization and the Critical Path to Improved Benefit-Risk Assessment of Drugs
• More

Spotlight on CPI Projects

• Dual Antiplatelet Therapy (DAPT) Trial - new
• Clinical Trials Transformation Initiative
• Drug Discovery Today Interviews CTTI
• CDRH Medical Device Fellowship Program
• News on Genetic Basis of Adverse Events
• MedWatch^Plus Update
• More

Multimedia

• More